Thrombolytic Agents: Nanocarriers in Targeted Release
A thrombus, known as a blood clot, may form within the vascular system of the body and impede blood flow. Thrombosis is the most common underlying pathology of cardiovascular diseases, contributing to high morbidity and mortality. However, the main thrombolytic drugs (urokinase, streptokinase, etc.)...
Saved in:
Main Authors: | Minghua Shen, Yujiao Wang, Fan Hu, Linwen Lv, Kui Chen, Gengmei Xing |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/f76ee979d4a648bc935a5093c0960f3a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Relationship and improvement strategies between drug nanocarrier characteristics and hemocompatibility: What can we learn from the literature
by: Shiqi Guo, et al.
Published: (2021) -
Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies
by: Alkaff SA, et al.
Published: (2020) -
Extracellular Vesicles – Advanced Nanocarriers in Cancer Therapy: Progress and Achievements
by: Huyan T, et al.
Published: (2020) -
Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective
by: Zhang J, et al.
Published: (2021) -
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
by: Cova E, et al.
Published: (2019)